Incidental Hepatocellular Carcinoma after Liver Transplantation: ClinicopathologicFeatures and Prognosis

Creative Commons License

Özdemir F., İnce V., Usta S., Carr B. I., Gözükara Bağ H. G., Akatlı A. N., ...Daha Fazla

AASLD - TASL Hepatology Connect Meeting, Ankara, Türkiye, 28 - 29 Nisan 2023, ss.1-2

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Ankara
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.1-2
  • İnönü Üniversitesi Adresli: Evet

Özet

The prognostic impact and clinicopathologic features of incidental hepatocellular carcinoma (iHCC) detected inexplanted livers of patients undergoing liver transplantation is a controversial issue in the previous studies whencompared with patients who are diagnosed as hepatocellular carcinoma (pdHCC) before liver transplantation. Weaimed to review and compare these patient groups in a high volume liver transplantation center.

Methods

The present study includes the retrospective data of 3204 patients who received liver transplantation betweenJanuary 2002 and April 2022.

Results

Of these 406 patients who have undergone liver transplantation for HCC, including 54 patients in this HCC groupdiagnosed incidentally after the pathological evaluation of the explanted livers. Most of the patients in the pdHCCgroup had moderately differentiated tumors (45.7 %). On the other hand most of the patients in the iHCC grouphad well differentiated tumors (79.6%) (Table). There were 158 (44%) patients who met the Milan criteria in thepdHCC group, while there were 48 (92%) patients in the iHCC group (p<0.001). IHCC patients have statisticallybetter 1,3,5 and 10 years disease free and overall survival rates when compared with pdHCC patients. There isonly 1 (1.85%) patient who had tumor recurrence in the iHCC group while 76 (21%) patients had tumorrecurrence in the pdHCC group (p=0.001) (Fig1). There is no disease free and overall survival difference wheniHCC patients compared with pdHCC patients who met Milan criteria (Fig2a). There is also no survival difference iniHCC patients when we dicotomize according to Milan criteria (Fig2b).

Conclusion

IHCC rate in our liver transplantation series is only 1.6%. iHCC tumors show better histopathologic features thanpdHCC with low recurence rate and iHCC patients have better survival than pdHCC patients. iHCC patients havesimilar survival and recurrence rates with within Milan pdHCC patients.